CYTOSORBENTS CORPORATION (NASDAQ:CTSO) Files An 8-K Financial Statements and Exhibits
Item 9.01
(d) Exhibits.
Cytosorbents Corp Exhibit
EX-99.1 2 tv511545_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 CytoSorbents Announces Expansion of CytoSorb® Partnership with Fresenius Medical Care Agreement brings innovative CytoSorb® therapy to Korea and Mexico and sets the stage for future growth MONMOUTH JUNCTION,…
To view the full exhibit click here
About CYTOSORBENTS CORPORATION (NASDAQ:CTSO)
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company’s CytoSorb is an extracorporeal cytokine filter and is designed to reduce the cytokine storm that causes inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury and pancreatitis. In addition, CytoSorb is used in other inflammatory conditions, such as cardiac surgery and autoimmune disease flares and cancer cachexia. It also has other products under development based upon its blood purification technology, including HemoDefend, ContrastSorb, DrugSorb, BetaSorb and others.
